Neurogenic Detrusor Overactivity Market Predicted to Grow at 7.7% CAGR During 2025–2029

 Get 20% Off Market Intelligence Reports With Code ONLINE20 — Track Global Tariffs, Economic Shifts, and Sector Transformations

 

 What Is the Estimated Market Growth Potential of the Neurogenic Detrusor Overactivity Market by 2029?
 The neurogenic detrusor overactivity market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing prevalence of neurological disorders, rising awareness among healthcare professionals, growing adoption of pharmaceutical interventions, expansion of hospital and clinic infrastructure, and increasing diagnosis rates.
 
 The neurogenic detrusor overactivity market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to a rising aging population, a growing prevalence of spinal cord injuries, increasing healthcare expenditure, expansion of minimally invasive treatment options, and rising patient awareness and education. Major trends in the forecast period include technology advancements in stem cell approaches, innovations in drug delivery systems, developments in neuromodulation devices, research and development in personalized medicine, and advancements in minimally invasive procedures.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24619&type=smp
 
 Which Major Growth Factors Are Shaping the Neurogenic Detrusor Overactivity Market?
 The rising incidence of neurological disorders is expected to propel the growth of the neurogenic detrusor overactivity market going forward. Neurological disorders refer to medical conditions that affect the brain, spinal cord, or nerves, leading to problems with movement, sensation, cognition, or other bodily functions. Neurological disorders are rising as people are living longer, which increases the chances of age-related brain degeneration. Neurogenic detrusor overactivity (NDO) is a bladder dysfunction commonly associated with neurological disorders, such as spinal cord injury, multiple sclerosis, and Parkinson’s disease. These conditions disrupt normal nerve signaling between the brain and bladder, leading to involuntary bladder contractions. For instance, in April 2024, according to a study published by the American Academy of Neurology (AAN), a US-based neurology and neuroscience organization, there will be an estimated 4.9 billion cases of brain disorders globally by 2050, a 22% increase from approximately 4 billion cases in 2021. Therefore, the rising incidence of neurological disorders is driving growth in the neurogenic detrusor overactivity market.
 
 What Are the Emerging Segments in the Neurogenic Detrusor Overactivity Market?
 The neurogenic detrusor overactivity market covered in this report is segmented — 
 
 1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment
 2) By Application: Adult, Child
 3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities
 
 Subsegments:
 1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies
 2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation
 3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment
 
 What Are the Major Trends Impacting the Neurogenic Detrusor Overactivity Market?
 Major companies operating in the neurogenic detrusor overactivity (NDO) treatment market are focusing on developing advanced generic therapeutics such as beta-3 adrenergic receptor agonists to deliver effective bladder control solutions at reduced costs. Beta-3 adrenergic receptor agonists, such as mirabegron, function by relaxing the detrusor muscle in the bladder, thereby increasing bladder capacity and reducing symptoms such as urgency and incontinence. For instance, in April 2024, Lupin Ltd., an India-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (USFDA) to launch Mirabegron, the generic version of Myrbetriq, in the United States. As an advanced once-daily oral therapy, Mirabegron offers a convenient and effective treatment option for patients with overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) in pediatric populations. This approval reinforces Lupin’s commitment to expanding access to high-quality, affordable generic medications in critical therapeutic areas.
 
 Which Companies Hold the Largest Share in the Neurogenic Detrusor Overactivity Market?
 Major companies operating in the neurogenic detrusor overactivity market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S. A., Medtronic plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries, Apotex Inc., Viatris Inc., Sumitomo Pharma America Inc., Galderma, Ipsen, Coloplast A/S, Aurobindo Pharma Limited, Hisamitsu Pharmaceutical Co. Inc., Kaken Pharmaceutical Co. Ltd., Hugel Inc. 
 
 Get the full neurogenic detrusor overactivity market report here:
 https://www.thebusinessresearchcompany.com/report/neurogenic-detrusor-overactivity-global-market-report
 
 Which Regions Are Driving the Most Demand in the Neurogenic Detrusor Overactivity Market?
 North America was the largest region in the neurogenic detrusor overactivity market in 2024. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company